基于EVIDEM医疗机构多准则循证决策框架评估伏诺拉生与艾普拉唑

Evaluating vonoprazan and ilaprazole based on EVIDEM multi-criteria evidence-based decision-making framework

目的:对富马酸伏诺拉生片与艾普拉唑肠溶片进行卫生技术评估,为医疗机构遴选药品提供证据。方法:使用课题组基于证据与价值对决策的影响(evidence and value impact on decision making,EVIDEM)建立的医疗机构药品遴选多准则循证决策框架(包括5个评估领域、13个评估准则)对两药进行评估,药品价值估算通过线性加权进行计算。结果:伏诺拉生与艾普拉唑在各评估领域价值估算分别为:临床需求0.36 vs.0.36、临床价值0.54 vs.0.51、患者价值0.46 vs.0.09、经济价值0.08 vs.0、社会影响0.48 vs.0.42,药品价值估算1.93 vs.1.37。结论:基于EVIDEM决策框架,伏诺拉生的评估结果优于艾普拉唑。EVIDEM决策框架可以将循证证据转化为药品价值估算,用于遴选药品的排序和比较,辅助决策者做出科学决策。

OBJECTIVE Evaluate vonoprazan fumarate tablets and ilaprazole enteric-coated tablets in order to provide certain evidence for drug selection in medical institutions.METHODS The multi-criteria evidence-based decision-making framework including 5 evaluation areas and 13 evaluation criterias established by the research group based on the evidence and value impact on decision making(EVIDEM)was used to evaluate vonoprazan and ilaprazole.The drug value estimation was calculated by linear weighting.RESULTS The value estimates of vonoprazan and ilaprazole in the five assessment areas were as follows:clinical demand 0.36 vs.0.36,clinical value 0.54 vs.0.51,patient value 0.46 vs.0.09,economic value 0.08 vs.0,social impact 0.48 vs.0.42,and the drug value estimate 1.93 vs.1.37.CONCLUSION Based on the EVIDEM decision-making framework,the evaluation results of vonoprazan are better than those of ilaprazole.The EVIDEM decision-making framework can transform evidence-based evidence into drug value estimates,which can be used to rank and compare selected drugs and assist decision makers in making scientific decisions.